Ontology highlight
ABSTRACT: Introduction
The efficacy of immunotherapy for treatment of patients with oligometastatic non-small cell lung cancer (NSCLC) at different metastatic sites remains controversial. We investigated the effect of different metastatic sites on immunotherapy for oligometastatic NSCLC following local treatment (LT).Methods
We retrospectively analyzed patients with oligometastatic NSCLC from the latest 2018 registry on the SEER Stat software (8.3.9. Version) and a Chinese single-center cohort. The effects of immunotherapy on OS (overall survival) and CSS (cancer specific survival) were estimated for patients with different metastatic sites.Results
A total of 483 patients in the SEER-18 database and 344 patients in the single-center cohort were included. Immunotherapy
SUBMITTER: Ma JC
PROVIDER: S-EPMC9702518 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature